Bigfoot Biomedical Secures $57M In New Funding To Support Commercialization Of Diabetes Management System
Executive Summary
As Bigfoot awaits FDA clearance for its Bigfoot Unity System, the diabetes treatment company’s business model calls for packing the System as part of a one-stop-shop monthly subscription model.
You may also be interested in...
Bigfoot Biomedical Closes $55M Series C Financing, Plans FDA Filing For Diabetes System
Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.
Tandem Wins FDA Clearance On First Stand-Alone Glycemic Controller
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
Harbinger Health Raised $140M In Series B To Further Develop First Blood-Based Cancer Test
Harbinger Health has raised a total of $190m since its founding in 2021. Its CEO Stephen Hahn told Medtech Insight in March that the company plans to develop a blood-based cancer test that is affordable, accessible and also more accurate than currently available tests.